Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report

Matthew J. Barth; Stanton Goldman; Lynette Smith; Sherrie Perkins; Bruce Shiramizu; Thomas G. Gross; Lauren Harrison; Warren Sanger; Mark B. Geyer; Lisa Giulino-Roth; Mitchell S. Cairo

doi:10.1111/bjh.12434

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report

Matthew J. Barth, Stanton Goldman, Lynette Smith, Sherrie Perkins, Bruce Shiramizu, Thomas G. Gross, Lauren Harrison, Warren Sanger, Mark B. Geyer, Lisa Giulino-Roth, Mitchell S. Cairo

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m²) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.

Original language	English (US)
Pages (from-to)	678-683
Number of pages	6
Journal	British Journal of Haematology
Volume	162
Issue number	5
DOIs	https://doi.org/10.1111/bjh.12434
State	Published - Sep 2013

Keywords

CD20
Non-Hodgkin lymphoma
Pediatric
Pharmacokinetics
Rituximab

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.12434

Cite this

Barth, M. J., Goldman, S., Smith, L., Perkins, S., Shiramizu, B., Gross, T. G., Harrison, L., Sanger, W., Geyer, M. B., Giulino-Roth, L., & Cairo, M. S. (2013). Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report. British Journal of Haematology, 162(5), 678-683. https://doi.org/10.1111/bjh.12434

Barth, MJ, Goldman, S, Smith, L, Perkins, S, Shiramizu, B, Gross, TG, Harrison, L, Sanger, W, Geyer, MB, Giulino-Roth, L & Cairo, MS 2013, 'Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report', British Journal of Haematology, vol. 162, no. 5, pp. 678-683. https://doi.org/10.1111/bjh.12434

@article{e33821b7fe8141478bdfecdd25ae8984,

title = "Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report",

abstract = "The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.",

keywords = "CD20, Non-Hodgkin lymphoma, Pediatric, Pharmacokinetics, Rituximab",

author = "Barth, {Matthew J.} and Stanton Goldman and Lynette Smith and Sherrie Perkins and Bruce Shiramizu and Gross, {Thomas G.} and Lauren Harrison and Warren Sanger and Geyer, {Mark B.} and Lisa Giulino-Roth and Cairo, {Mitchell S.}",

year = "2013",

month = sep,

doi = "10.1111/bjh.12434",

language = "English (US)",

volume = "162",

pages = "678--683",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia

T2 - A Children's Oncology Group report

AU - Barth, Matthew J.

AU - Goldman, Stanton

AU - Smith, Lynette

AU - Perkins, Sherrie

AU - Shiramizu, Bruce

AU - Gross, Thomas G.

AU - Harrison, Lauren

AU - Sanger, Warren

AU - Geyer, Mark B.

AU - Giulino-Roth, Lisa

AU - Cairo, Mitchell S.

PY - 2013/9

Y1 - 2013/9

N2 - The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.

AB - The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.

KW - CD20

KW - Non-Hodgkin lymphoma

KW - Pediatric

KW - Pharmacokinetics

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84881663487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881663487&partnerID=8YFLogxK

U2 - 10.1111/bjh.12434

DO - 10.1111/bjh.12434

M3 - Article

C2 - 23802659

AN - SCOPUS:84881663487

SN - 0007-1048

VL - 162

SP - 678

EP - 683

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this